Proresolving Actions of Synthetic and Natural Protease Inhibitors Are Mediated by Annexin A1

Annexin A1 (AnxA1) is a glucocorticoid-regulated protein endowed with anti-inflammatory and proresolving properties. Intact AnxA1 is a 37-kDa protein that may be cleaved in vivo at the N-terminal region by neutrophil proteases including elastase and proteinase-3, generating the 33-kDa isoform that i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of immunology (1950) 2016-02, Vol.196 (4), p.1922-1932
Hauptverfasser: Vago, Juliana P, Tavares, Luciana P, Sugimoto, Michelle A, Lima, Graziele Letícia N, Galvão, Izabela, de Caux, Thais R, Lima, Kátia M, Ribeiro, Ana Luíza C, Carneiro, Fernanda S, Nunes, Fernanda Freire C, Pinho, Vanessa, Perretti, Mauro, Teixeira, Mauro M, Sousa, Lirlândia P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1932
container_issue 4
container_start_page 1922
container_title The Journal of immunology (1950)
container_volume 196
creator Vago, Juliana P
Tavares, Luciana P
Sugimoto, Michelle A
Lima, Graziele Letícia N
Galvão, Izabela
de Caux, Thais R
Lima, Kátia M
Ribeiro, Ana Luíza C
Carneiro, Fernanda S
Nunes, Fernanda Freire C
Pinho, Vanessa
Perretti, Mauro
Teixeira, Mauro M
Sousa, Lirlândia P
description Annexin A1 (AnxA1) is a glucocorticoid-regulated protein endowed with anti-inflammatory and proresolving properties. Intact AnxA1 is a 37-kDa protein that may be cleaved in vivo at the N-terminal region by neutrophil proteases including elastase and proteinase-3, generating the 33-kDa isoform that is largely inactive. In this study, we investigated the dynamics of AnxA1 expression and the effects of synthetic (sivelestat [SIV]; Eglin) and natural (secretory leukocyte protease inhibitor [SLPI]; Elafin) protease inhibitors on the resolution of LPS-induced inflammation. During the settings of LPS inflammation AnxA1 cleavage associated closely with the peak of neutrophil and elastase expression and activity. SLPI expression increased during resolving phase of the pleurisy. Therapeutic treatment of LPS-challenge mice with recombinant human SLPI or Elafin accelerated resolution, an effect associated with increased numbers of apoptotic neutrophils in the pleural exudates, inhibition of elastase, and modulation of the survival-controlling proteins NF-κB and Mcl-1. Similar effects were observed with SIV, which dose-dependently inhibited neutrophil elastase and shortened resolution intervals. Mechanistically, SIV-induced resolution was caspase-dependent, associated to increased levels of intact AnxA1 and decreased expression of NF-κB and Mcl-1. The proresolving effect of antiproteases was also observed in a model of monosodium urate crystals-induced inflammation. SIV skewed macrophages toward resolving phenotypes and enhanced efferocytosis of apoptotic neutrophils. A neutralizing antiserum against AnxA1 and a nonselective antagonist of AnxA1 receptor abolished the accelerated resolution promoted by SIV. Collectively, these results show that elastase inhibition not only inhibits inflammation but actually promotes resolution, and this response is mediated by protection of endogenous intact AnxA1 with ensuing augmentation of neutrophil apoptosis.
doi_str_mv 10.4049/jimmunol.1500886
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_4049_jimmunol_1500886</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>26800869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c341t-afbd298d910ba7f1473298be25bdb8d9e75a600871c276c6070f2f16e09ce9e93</originalsourceid><addsrcrecordid>eNo9kF1LwzAUhoMobk7vvZL8gc6TtE3ayzL8GMwPUO-EkrSnLqNNR5KJ_fdWtnl1eA_vczg8hFwzmCeQ5Lcb03U727dzlgJkmTghU5amEAkB4pRMATiPmBRyQi683wCAAJ6ckwkX2dgX-ZR8vrreoe_bb2O_aFEF01tP-4a-DTasMZiKKlvTZxV2TrV0bAdUHunSro02oXeeFg7pE9ZGBaypHmhhLf4YSwt2Sc4a1Xq8OswZ-bi_e188RquXh-WiWEVVnLAQqUbXPM_qnIFWsmGJjMeokae61uMaZarE-K9kFZeiEiCh4Q0TCHmFOebxjMD-buV67x025daZTrmhZFD-iSqPosqDqBG52SPbne6w_geOZuJfNa1mvw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Proresolving Actions of Synthetic and Natural Protease Inhibitors Are Mediated by Annexin A1</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Vago, Juliana P ; Tavares, Luciana P ; Sugimoto, Michelle A ; Lima, Graziele Letícia N ; Galvão, Izabela ; de Caux, Thais R ; Lima, Kátia M ; Ribeiro, Ana Luíza C ; Carneiro, Fernanda S ; Nunes, Fernanda Freire C ; Pinho, Vanessa ; Perretti, Mauro ; Teixeira, Mauro M ; Sousa, Lirlândia P</creator><creatorcontrib>Vago, Juliana P ; Tavares, Luciana P ; Sugimoto, Michelle A ; Lima, Graziele Letícia N ; Galvão, Izabela ; de Caux, Thais R ; Lima, Kátia M ; Ribeiro, Ana Luíza C ; Carneiro, Fernanda S ; Nunes, Fernanda Freire C ; Pinho, Vanessa ; Perretti, Mauro ; Teixeira, Mauro M ; Sousa, Lirlândia P</creatorcontrib><description>Annexin A1 (AnxA1) is a glucocorticoid-regulated protein endowed with anti-inflammatory and proresolving properties. Intact AnxA1 is a 37-kDa protein that may be cleaved in vivo at the N-terminal region by neutrophil proteases including elastase and proteinase-3, generating the 33-kDa isoform that is largely inactive. In this study, we investigated the dynamics of AnxA1 expression and the effects of synthetic (sivelestat [SIV]; Eglin) and natural (secretory leukocyte protease inhibitor [SLPI]; Elafin) protease inhibitors on the resolution of LPS-induced inflammation. During the settings of LPS inflammation AnxA1 cleavage associated closely with the peak of neutrophil and elastase expression and activity. SLPI expression increased during resolving phase of the pleurisy. Therapeutic treatment of LPS-challenge mice with recombinant human SLPI or Elafin accelerated resolution, an effect associated with increased numbers of apoptotic neutrophils in the pleural exudates, inhibition of elastase, and modulation of the survival-controlling proteins NF-κB and Mcl-1. Similar effects were observed with SIV, which dose-dependently inhibited neutrophil elastase and shortened resolution intervals. Mechanistically, SIV-induced resolution was caspase-dependent, associated to increased levels of intact AnxA1 and decreased expression of NF-κB and Mcl-1. The proresolving effect of antiproteases was also observed in a model of monosodium urate crystals-induced inflammation. SIV skewed macrophages toward resolving phenotypes and enhanced efferocytosis of apoptotic neutrophils. A neutralizing antiserum against AnxA1 and a nonselective antagonist of AnxA1 receptor abolished the accelerated resolution promoted by SIV. Collectively, these results show that elastase inhibition not only inhibits inflammation but actually promotes resolution, and this response is mediated by protection of endogenous intact AnxA1 with ensuing augmentation of neutrophil apoptosis.</description><identifier>ISSN: 0022-1767</identifier><identifier>EISSN: 1550-6606</identifier><identifier>DOI: 10.4049/jimmunol.1500886</identifier><identifier>PMID: 26800869</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Annexin A1 - immunology ; Apoptosis - drug effects ; Blotting, Western ; Flow Cytometry ; Glycine - analogs &amp; derivatives ; Glycine - pharmacology ; Humans ; Inflammation - immunology ; Inflammation - metabolism ; Leukocyte Elastase - immunology ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Transgenic ; Neutrophils - immunology ; Protease Inhibitors - metabolism ; Protease Inhibitors - pharmacology ; Secretory Leukocyte Peptidase Inhibitor - metabolism ; Secretory Leukocyte Peptidase Inhibitor - pharmacology ; Sulfonamides - pharmacology</subject><ispartof>The Journal of immunology (1950), 2016-02, Vol.196 (4), p.1922-1932</ispartof><rights>Copyright © 2016 by The American Association of Immunologists, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c341t-afbd298d910ba7f1473298be25bdb8d9e75a600871c276c6070f2f16e09ce9e93</citedby><cites>FETCH-LOGICAL-c341t-afbd298d910ba7f1473298be25bdb8d9e75a600871c276c6070f2f16e09ce9e93</cites><orcidid>0000-0002-3243-8424 ; 0000-0002-1042-9762 ; 0000-0002-6944-3008 ; 0000-0003-1038-2324 ; 0000-0003-2068-3331 ; 0000-0001-8188-3738 ; 0000-0002-4527-6065</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26800869$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vago, Juliana P</creatorcontrib><creatorcontrib>Tavares, Luciana P</creatorcontrib><creatorcontrib>Sugimoto, Michelle A</creatorcontrib><creatorcontrib>Lima, Graziele Letícia N</creatorcontrib><creatorcontrib>Galvão, Izabela</creatorcontrib><creatorcontrib>de Caux, Thais R</creatorcontrib><creatorcontrib>Lima, Kátia M</creatorcontrib><creatorcontrib>Ribeiro, Ana Luíza C</creatorcontrib><creatorcontrib>Carneiro, Fernanda S</creatorcontrib><creatorcontrib>Nunes, Fernanda Freire C</creatorcontrib><creatorcontrib>Pinho, Vanessa</creatorcontrib><creatorcontrib>Perretti, Mauro</creatorcontrib><creatorcontrib>Teixeira, Mauro M</creatorcontrib><creatorcontrib>Sousa, Lirlândia P</creatorcontrib><title>Proresolving Actions of Synthetic and Natural Protease Inhibitors Are Mediated by Annexin A1</title><title>The Journal of immunology (1950)</title><addtitle>J Immunol</addtitle><description>Annexin A1 (AnxA1) is a glucocorticoid-regulated protein endowed with anti-inflammatory and proresolving properties. Intact AnxA1 is a 37-kDa protein that may be cleaved in vivo at the N-terminal region by neutrophil proteases including elastase and proteinase-3, generating the 33-kDa isoform that is largely inactive. In this study, we investigated the dynamics of AnxA1 expression and the effects of synthetic (sivelestat [SIV]; Eglin) and natural (secretory leukocyte protease inhibitor [SLPI]; Elafin) protease inhibitors on the resolution of LPS-induced inflammation. During the settings of LPS inflammation AnxA1 cleavage associated closely with the peak of neutrophil and elastase expression and activity. SLPI expression increased during resolving phase of the pleurisy. Therapeutic treatment of LPS-challenge mice with recombinant human SLPI or Elafin accelerated resolution, an effect associated with increased numbers of apoptotic neutrophils in the pleural exudates, inhibition of elastase, and modulation of the survival-controlling proteins NF-κB and Mcl-1. Similar effects were observed with SIV, which dose-dependently inhibited neutrophil elastase and shortened resolution intervals. Mechanistically, SIV-induced resolution was caspase-dependent, associated to increased levels of intact AnxA1 and decreased expression of NF-κB and Mcl-1. The proresolving effect of antiproteases was also observed in a model of monosodium urate crystals-induced inflammation. SIV skewed macrophages toward resolving phenotypes and enhanced efferocytosis of apoptotic neutrophils. A neutralizing antiserum against AnxA1 and a nonselective antagonist of AnxA1 receptor abolished the accelerated resolution promoted by SIV. Collectively, these results show that elastase inhibition not only inhibits inflammation but actually promotes resolution, and this response is mediated by protection of endogenous intact AnxA1 with ensuing augmentation of neutrophil apoptosis.</description><subject>Animals</subject><subject>Annexin A1 - immunology</subject><subject>Apoptosis - drug effects</subject><subject>Blotting, Western</subject><subject>Flow Cytometry</subject><subject>Glycine - analogs &amp; derivatives</subject><subject>Glycine - pharmacology</subject><subject>Humans</subject><subject>Inflammation - immunology</subject><subject>Inflammation - metabolism</subject><subject>Leukocyte Elastase - immunology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Transgenic</subject><subject>Neutrophils - immunology</subject><subject>Protease Inhibitors - metabolism</subject><subject>Protease Inhibitors - pharmacology</subject><subject>Secretory Leukocyte Peptidase Inhibitor - metabolism</subject><subject>Secretory Leukocyte Peptidase Inhibitor - pharmacology</subject><subject>Sulfonamides - pharmacology</subject><issn>0022-1767</issn><issn>1550-6606</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kF1LwzAUhoMobk7vvZL8gc6TtE3ayzL8GMwPUO-EkrSnLqNNR5KJ_fdWtnl1eA_vczg8hFwzmCeQ5Lcb03U727dzlgJkmTghU5amEAkB4pRMATiPmBRyQi683wCAAJ6ckwkX2dgX-ZR8vrreoe_bb2O_aFEF01tP-4a-DTasMZiKKlvTZxV2TrV0bAdUHunSro02oXeeFg7pE9ZGBaypHmhhLf4YSwt2Sc4a1Xq8OswZ-bi_e188RquXh-WiWEVVnLAQqUbXPM_qnIFWsmGJjMeokae61uMaZarE-K9kFZeiEiCh4Q0TCHmFOebxjMD-buV67x025daZTrmhZFD-iSqPosqDqBG52SPbne6w_geOZuJfNa1mvw</recordid><startdate>20160215</startdate><enddate>20160215</enddate><creator>Vago, Juliana P</creator><creator>Tavares, Luciana P</creator><creator>Sugimoto, Michelle A</creator><creator>Lima, Graziele Letícia N</creator><creator>Galvão, Izabela</creator><creator>de Caux, Thais R</creator><creator>Lima, Kátia M</creator><creator>Ribeiro, Ana Luíza C</creator><creator>Carneiro, Fernanda S</creator><creator>Nunes, Fernanda Freire C</creator><creator>Pinho, Vanessa</creator><creator>Perretti, Mauro</creator><creator>Teixeira, Mauro M</creator><creator>Sousa, Lirlândia P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-3243-8424</orcidid><orcidid>https://orcid.org/0000-0002-1042-9762</orcidid><orcidid>https://orcid.org/0000-0002-6944-3008</orcidid><orcidid>https://orcid.org/0000-0003-1038-2324</orcidid><orcidid>https://orcid.org/0000-0003-2068-3331</orcidid><orcidid>https://orcid.org/0000-0001-8188-3738</orcidid><orcidid>https://orcid.org/0000-0002-4527-6065</orcidid></search><sort><creationdate>20160215</creationdate><title>Proresolving Actions of Synthetic and Natural Protease Inhibitors Are Mediated by Annexin A1</title><author>Vago, Juliana P ; Tavares, Luciana P ; Sugimoto, Michelle A ; Lima, Graziele Letícia N ; Galvão, Izabela ; de Caux, Thais R ; Lima, Kátia M ; Ribeiro, Ana Luíza C ; Carneiro, Fernanda S ; Nunes, Fernanda Freire C ; Pinho, Vanessa ; Perretti, Mauro ; Teixeira, Mauro M ; Sousa, Lirlândia P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c341t-afbd298d910ba7f1473298be25bdb8d9e75a600871c276c6070f2f16e09ce9e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Annexin A1 - immunology</topic><topic>Apoptosis - drug effects</topic><topic>Blotting, Western</topic><topic>Flow Cytometry</topic><topic>Glycine - analogs &amp; derivatives</topic><topic>Glycine - pharmacology</topic><topic>Humans</topic><topic>Inflammation - immunology</topic><topic>Inflammation - metabolism</topic><topic>Leukocyte Elastase - immunology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Transgenic</topic><topic>Neutrophils - immunology</topic><topic>Protease Inhibitors - metabolism</topic><topic>Protease Inhibitors - pharmacology</topic><topic>Secretory Leukocyte Peptidase Inhibitor - metabolism</topic><topic>Secretory Leukocyte Peptidase Inhibitor - pharmacology</topic><topic>Sulfonamides - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vago, Juliana P</creatorcontrib><creatorcontrib>Tavares, Luciana P</creatorcontrib><creatorcontrib>Sugimoto, Michelle A</creatorcontrib><creatorcontrib>Lima, Graziele Letícia N</creatorcontrib><creatorcontrib>Galvão, Izabela</creatorcontrib><creatorcontrib>de Caux, Thais R</creatorcontrib><creatorcontrib>Lima, Kátia M</creatorcontrib><creatorcontrib>Ribeiro, Ana Luíza C</creatorcontrib><creatorcontrib>Carneiro, Fernanda S</creatorcontrib><creatorcontrib>Nunes, Fernanda Freire C</creatorcontrib><creatorcontrib>Pinho, Vanessa</creatorcontrib><creatorcontrib>Perretti, Mauro</creatorcontrib><creatorcontrib>Teixeira, Mauro M</creatorcontrib><creatorcontrib>Sousa, Lirlândia P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Journal of immunology (1950)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vago, Juliana P</au><au>Tavares, Luciana P</au><au>Sugimoto, Michelle A</au><au>Lima, Graziele Letícia N</au><au>Galvão, Izabela</au><au>de Caux, Thais R</au><au>Lima, Kátia M</au><au>Ribeiro, Ana Luíza C</au><au>Carneiro, Fernanda S</au><au>Nunes, Fernanda Freire C</au><au>Pinho, Vanessa</au><au>Perretti, Mauro</au><au>Teixeira, Mauro M</au><au>Sousa, Lirlândia P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proresolving Actions of Synthetic and Natural Protease Inhibitors Are Mediated by Annexin A1</atitle><jtitle>The Journal of immunology (1950)</jtitle><addtitle>J Immunol</addtitle><date>2016-02-15</date><risdate>2016</risdate><volume>196</volume><issue>4</issue><spage>1922</spage><epage>1932</epage><pages>1922-1932</pages><issn>0022-1767</issn><eissn>1550-6606</eissn><abstract>Annexin A1 (AnxA1) is a glucocorticoid-regulated protein endowed with anti-inflammatory and proresolving properties. Intact AnxA1 is a 37-kDa protein that may be cleaved in vivo at the N-terminal region by neutrophil proteases including elastase and proteinase-3, generating the 33-kDa isoform that is largely inactive. In this study, we investigated the dynamics of AnxA1 expression and the effects of synthetic (sivelestat [SIV]; Eglin) and natural (secretory leukocyte protease inhibitor [SLPI]; Elafin) protease inhibitors on the resolution of LPS-induced inflammation. During the settings of LPS inflammation AnxA1 cleavage associated closely with the peak of neutrophil and elastase expression and activity. SLPI expression increased during resolving phase of the pleurisy. Therapeutic treatment of LPS-challenge mice with recombinant human SLPI or Elafin accelerated resolution, an effect associated with increased numbers of apoptotic neutrophils in the pleural exudates, inhibition of elastase, and modulation of the survival-controlling proteins NF-κB and Mcl-1. Similar effects were observed with SIV, which dose-dependently inhibited neutrophil elastase and shortened resolution intervals. Mechanistically, SIV-induced resolution was caspase-dependent, associated to increased levels of intact AnxA1 and decreased expression of NF-κB and Mcl-1. The proresolving effect of antiproteases was also observed in a model of monosodium urate crystals-induced inflammation. SIV skewed macrophages toward resolving phenotypes and enhanced efferocytosis of apoptotic neutrophils. A neutralizing antiserum against AnxA1 and a nonselective antagonist of AnxA1 receptor abolished the accelerated resolution promoted by SIV. Collectively, these results show that elastase inhibition not only inhibits inflammation but actually promotes resolution, and this response is mediated by protection of endogenous intact AnxA1 with ensuing augmentation of neutrophil apoptosis.</abstract><cop>United States</cop><pmid>26800869</pmid><doi>10.4049/jimmunol.1500886</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-3243-8424</orcidid><orcidid>https://orcid.org/0000-0002-1042-9762</orcidid><orcidid>https://orcid.org/0000-0002-6944-3008</orcidid><orcidid>https://orcid.org/0000-0003-1038-2324</orcidid><orcidid>https://orcid.org/0000-0003-2068-3331</orcidid><orcidid>https://orcid.org/0000-0001-8188-3738</orcidid><orcidid>https://orcid.org/0000-0002-4527-6065</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-1767
ispartof The Journal of immunology (1950), 2016-02, Vol.196 (4), p.1922-1932
issn 0022-1767
1550-6606
language eng
recordid cdi_crossref_primary_10_4049_jimmunol_1500886
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Animals
Annexin A1 - immunology
Apoptosis - drug effects
Blotting, Western
Flow Cytometry
Glycine - analogs & derivatives
Glycine - pharmacology
Humans
Inflammation - immunology
Inflammation - metabolism
Leukocyte Elastase - immunology
Male
Mice
Mice, Inbred BALB C
Mice, Transgenic
Neutrophils - immunology
Protease Inhibitors - metabolism
Protease Inhibitors - pharmacology
Secretory Leukocyte Peptidase Inhibitor - metabolism
Secretory Leukocyte Peptidase Inhibitor - pharmacology
Sulfonamides - pharmacology
title Proresolving Actions of Synthetic and Natural Protease Inhibitors Are Mediated by Annexin A1
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T11%3A35%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proresolving%20Actions%20of%20Synthetic%20and%20Natural%20Protease%20Inhibitors%20Are%20Mediated%20by%20Annexin%20A1&rft.jtitle=The%20Journal%20of%20immunology%20(1950)&rft.au=Vago,%20Juliana%20P&rft.date=2016-02-15&rft.volume=196&rft.issue=4&rft.spage=1922&rft.epage=1932&rft.pages=1922-1932&rft.issn=0022-1767&rft.eissn=1550-6606&rft_id=info:doi/10.4049/jimmunol.1500886&rft_dat=%3Cpubmed_cross%3E26800869%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26800869&rfr_iscdi=true